Mayne Pharma closes acquisition of Teva, Allergan products

GREENVILLE, N.C. — Mayne Pharma recently announced that it had closed its $652 million acquisition of 42 products from Teva and Allergan. The portfolio includes 37 approved products and five products currently awaiting approval. The acquisition makes Mayne Pharma one of the 25 largest retail generic pharmaceutical companies in the United States and the second-largest generic oral contraceptive provider, the company said. 
 
“We are extremely pleased to complete this transaction that establishes Mayne Pharma as a key player in the U.S. generic market,” president Stefan Cross said. “This portfolio is highly profitable and will significantly extend our size, scale and reach in the United States. Recent investments in people, systems and facilities will readily support the rapidly growing organization and ensure we continue to deliver exceptional service and high-quality products to our customers.”
 
The company has recently invested in a new manufacturing facility in Greenville, N.C., that will increase its manufacturing capacity by a factor of more than four. It has also grown its workforce by more than 700 employees globally. 
 
The products acquired include the following in different dosage strengths. 
 
  • Amethia Lo 
  • Amethia 
  • Azurette 
  • Camila 
  • Carbidopa/Levodopa 
  • Caziant Tablets 
  • Clarithromycin Ext Release 
  • Clonidine 
  • Clozapine 
  • Cyclosporine 
  • Dextroamphetamine Sulfate ER
  • Diazepam
  • Disopyramide Phosphate 
  • Errin 
  • Estazolam 
  • Estradiol 
  • Fluocinonide 
  • Leena 
  • Levora 
  • Low-Ogestrel 
  • Lutera 
  • Methylphenidate ER
  • Microgestin 1/20
  • Microgestin Fe 1/20
  • Microgestin 1.5/30
  • Microgestin Fe 1.5/30
  • Necon 
  • Nortriptyline Hydrochloride 
  • Sronyx 
  • Tamoxifen Citrate 
  • Tilia Fe 
  • Trimethoprim 
  • Tri-Norinyl 
  • Trivora 
  • Zarah 
  • Zovia 
 
Login or Register to post a comment.